These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 33288923)

  • 21. Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus.
    Klausberger M; Tscheliessnig R; Neff S; Nachbagauer R; Wohlbold TJ; Wilde M; Palmberger D; Krammer F; Jungbauer A; Grabherr R
    PLoS One; 2016; 11(4):e0153579. PubMed ID: 27088239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults.
    Widge AT; Hofstetter AR; Houser KV; Awan SF; Chen GL; Burgos Florez MC; Berkowitz NM; Mendoza F; Hendel CS; Holman LA; Gordon IJ; Apte P; Liang CJ; Gaudinski MR; Coates EE; Strom L; Wycuff D; Vazquez S; Stein JA; Gall JG; Adams WC; Carlton K; Gillespie RA; Creanga A; Crank MC; Andrews SF; Castro M; Serebryannyy LA; Narpala SR; Hatcher C; Lin BC; O'Connell S; Freyn AW; Rosado VC; Nachbagauer R; Palese P; Kanekiyo M; McDermott AB; Koup RA; Dropulic LK; Graham BS; Mascola JR; Ledgerwood JE;
    Sci Transl Med; 2023 Apr; 15(692):eade4790. PubMed ID: 37075129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Universal Influenza Vaccine Approaches Using Full-Length or Head-Only Hemagglutinin Proteins.
    Ross TM
    J Infect Dis; 2019 Apr; 219(Suppl_1):S57-S61. PubMed ID: 30715379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice.
    Broecker F; Liu STH; Sun W; Krammer F; Simon V; Palese P
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30045991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.
    Yang JR; Cheng CY; Chen CY; Lin CH; Kuo CY; Huang HY; Wu FT; Yang YC; Wu CY; Liu MT; Hsiao PW
    Antiviral Res; 2017 Apr; 140():62-75. PubMed ID: 28093338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.
    He W; Mullarkey CE; Duty JA; Moran TM; Palese P; Miller MS
    J Virol; 2015 Apr; 89(7):3610-8. PubMed ID: 25589655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influenza vaccine: progress in a vaccine that elicits a broad immune response.
    Isakova-Sivak I; Stepanova E; Mezhenskaya D; Matyushenko V; Prokopenko P; Sychev I; Wong PF; Rudenko L
    Expert Rev Vaccines; 2021 Sep; 20(9):1097-1112. PubMed ID: 34348561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection.
    de Vries RD; Nieuwkoop NJ; Pronk M; de Bruin E; Leroux-Roels G; Huijskens EGW; van Binnendijk RS; Krammer F; Koopmans MPG; Rimmelzwaan GF
    Vaccine; 2017 Jan; 35(2):238-247. PubMed ID: 27914742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seasonal influenza vaccines.
    Fiore AE; Bridges CB; Cox NJ
    Curr Top Microbiol Immunol; 2009; 333():43-82. PubMed ID: 19768400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.
    Langley JM; Frenette L; Ferguson L; Riff D; Sheldon E; Risi G; Johnson C; Li P; Kenney R; Innis B; Fries L
    J Infect Dis; 2010 Jun; 201(11):1644-53. PubMed ID: 20423222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans.
    Nachbagauer R; Choi A; Izikson R; Cox MM; Palese P; Krammer F
    mBio; 2016 Jan; 7(1):e01996-15. PubMed ID: 26787832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
    Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
    Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity of modified vaccinia virus Ankara expressing the hemagglutinin stalk domain of pandemic (H1N1) 2009 influenza virus.
    Di Mario G; Soprana E; Gubinelli F; Panigada M; Facchini M; Fabiani C; Garulli B; Basileo M; Cassone A; Siccardi A; Donatelli I; Castrucci MR
    Pathog Glob Health; 2017 Mar; 111(2):69-75. PubMed ID: 28081672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice.
    Nachbagauer R; Kinzler D; Choi A; Hirsh A; Beaulieu E; Lecrenier N; Innis BL; Palese P; Mallett CP; Krammer F
    NPJ Vaccines; 2016; 1():16015-. PubMed ID: 29250436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conformational Stability of the Hemagglutinin of H5N1 Influenza A Viruses Influences Susceptibility to Broadly Neutralizing Stem Antibodies.
    Wang W; Song HS; Keller PW; Alvarado-Facundo E; Vassell R; Weiss CD
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
    Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
    J Virol; 2017 May; 91(9):. PubMed ID: 28179535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
    Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progress on adenovirus-vectored universal influenza vaccines.
    Xiang K; Ying G; Yan Z; Shanshan Y; Lei Z; Hongjun L; Maosheng S
    Hum Vaccin Immunother; 2015; 11(5):1209-22. PubMed ID: 25876176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of an AS03(A)-adjuvanted H5N1 influenza vaccine in a Taiwanese population.
    Hwang SJ; Chang SC; Yu CJ; Chan YJ; Chen TJ; Hsieh SL; Lai HY; Lin MH; Liu JY; Ong G; Roman F; Dramé M; Bock HL; Yang PC
    J Formos Med Assoc; 2011 Dec; 110(12):780-6. PubMed ID: 22248833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.